Deerfield
Deerfield is an investment firm that transforms healthcare through information, investment, and philanthropy.
Business Model:
Revenue: $20M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Deerfield Information
Geographic Data
Address: 345 Park Avenue South
City: New York
State: NY
Zip: 10010
Country: US
Financial Info
Stage:
Raised Last:
$25M
Raised Total:$25M
Social
Linkedin
Crunchbase
Metrics
1,373,580Website Global Rank
17,484Website Monthly Traffic
Twitter Followers
Description
Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.
Contact Phone:
+12125511600
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2014 | Kolltan Pharmaceuticals | Series D | 60M |
| 7/2022 | Vicinitas Therapeutics | Series A | 65M |
| 3/2020 | RubiconMD | Series C | 18M |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 8/2015 | Rhythm Metabolic | Series A | 40M |
| 4/2021 | Jaguar Gene Therapy | Series B | 0 |
| 3/2021 | Xeris Pharmaceuticals | Post-IPO Equity | 27M |
| 12/2020 | Cystetic Medicines | Funding Round | 0 |
| 9/2013 | IMRIS Inc. | Post-IPO Debt | 36.8M |
| 2/2013 | Éclat Pharmaceuticals | Post-IPO Debt | 10.5M |
| 3/2011 | Titan Pharmaceuticals | Post-IPO Debt | 20M |
| 2/2020 | Farapulse | Venture Round | - |
| 9/2018 | Poseidon Innovation | Venture Round | 65M |
| 12/2020 | Octave Bioscience | Series B | 32M |
| 3/2014 | Wellfount | Venture Round | 15M |
| 9/2016 | SentreHEART | Series D | 35M |
| 3/2015 | EndoChoice | Series D | 57M |
| 1/2021 | MIVI Neuroscience | Series B | 35M |
| 11/2021 | The Oncology Institute of Hope and Innovation | Post-IPO Equity | 275M |
| 5/2016 | Homology Medicines | Series A | 43.5M |
| 10/2022 | Pleno | Series A | 0 |
| 2/2022 | Somatus | Series E | 0 |
| 3/2021 | Crossover Health | Series D | 0 |
| 9/2008 | Ista Pharmaceuticals | Debt Financing | 65M |
| 6/2015 | NeoChord | Series C | 0 |
| 4/2016 | Lumos Pharma | Series B | 34M |
| 9/2021 | HilleVax | Equity | 135M |
| 12/2014 | Conventus Orthopaedics | Series A | 0 |
| 6/2018 | Appello Pharmaceuticals | Series A | 15.5M |
| 4/2021 | Cohere Health | Series B | 36.1M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2016 | Blade Therapeutics | Series B | 45M |
| 3/2018 | Dracen Pharmaceuticals | Series A | 40M |
| 4/2018 | Sollis Therapeutics | Venture Round | 0 |
| 8/2021 | ARS Pharmaceuticals | Series D | 55M |
| 5/2021 | Nuvalent | Series B | 0 |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 5/2014 | Proteon Therapeutics | Series D | 0 |
| 7/2021 | Strata Oncology | Series C | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 6/2009 | Arena Pharmaceuticals | Post-IPO Equity | 151.8M |
| 11/2014 | Alimera Sciences | Post-IPO Equity | 50M |
| 5/2020 | CorVent Medical | Seed Round | 0 |
| 7/2012 | Nektar Therapeutics | Post-IPO Debt | 125M |
| 11/2020 | Bridge Medicines | Equity | 10M |
| 9/2018 | ARS Pharmaceuticals | Series C | 20M |
| 10/2020 | InCarda Therapeutics | Series C | 30M |
| 6/2018 | Cureatr | Venture Round | 3M |
| 5/2021 | ADC Therapeutics | Post-IPO Debt | 50M |
| 2/2021 | Pairwise Plants | Series B | 90M |
| 9/2022 | Innervace | Series A | 40M |
| 11/2013 | TriVascular | Series E | 0 |
| 4/2018 | V-Wave | Series C | 0 |
| 10/2021 | Lark | Series D | 0 |
| 12/2021 | Hyperfine | Post-IPO Equity | 0 |
| 2/2015 | Tonix Pharmaceuticals | Post-IPO Equity | 28.7M |
| 6/2015 | Cureatr | Series B | 0 |
| 4/2014 | Adverum Biotechnologies | Series B | 55M |
| 10/2017 | Phoenix | Venture Round | 12M |
| 6/2023 | Presidio Medical | Series C | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 11/2022 | Abeona Therapeutics | Post-IPO Equity | 0 |
| 11/2022 | Intus Care | Series A | 0 |
| 6/2021 | Synthekine | Series B | 0 |
| 1/2019 | Schrödinger | Series E | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 9/2020 | Ready | Series C | 54M |
| 10/2015 | American Addiction Centers | Post-IPO Equity | 100M |
| 5/2020 | Intersect ENT | Post-IPO Equity | 65M |
| 7/2013 | MannKind | Post-IPO Debt | 160M |
| 7/2017 | Farapulse | Venture Round | 5M |
| 6/2021 | Novocardia | Series A | 53.7M |
| 8/2020 | Reprieve Cardiovascular | Series A | 15M |
| 6/2022 | Insilico Medicine | Series D | 0 |
| 1/2016 | Aprecia Pharmaceuticals | Venture Round | 35M |
| 3/2019 | TriNetX | Series D | 40M |
| 12/2015 | Recovery Centers of America | Private Equity Round | 231.5M |
| 1/2016 | Xeris Pharmaceuticals | Series C | 41M |
| 3/2016 | Acutus Medical | Series C | 75M |
| 5/2019 | Aerie Pharmaceuticals | Post-IPO Debt | 200M |
| 7/2020 | Annexon Biosciences | Series C | 100M |
| 3/2009 | Insulet | Post-IPO Debt | 60M |
| 4/2014 | Infinity Pharmaceuticals | Post-IPO Debt | 100M |
| 2/2021 | Jaguar Gene Therapy | Series A | - |
| 6/2017 | Aziyo Biologics | Venture Round | 12M |
| 9/2010 | New American Therapeutics | Venture Round | 53M |
| 1/2016 | ESSA Pharma | Post-IPO Equity | 15M |
| 6/2014 | KemPharm | Debt Financing | 60M |
| 9/2020 | V-Wave | Series C | 0 |
| 2/2013 | PacBio | Post-IPO Debt | 20.5M |
| 4/2013 | SERMO | Venture Round | 35M |
| 6/2010 | Exelixis | Post-IPO Debt | 160M |
| 1/2011 | Veterinary Practice Partners | Venture Round | 10M |
| 4/2021 | Vesta Healthcare | Venture Round | 65M |
| 5/2011 | WaferGen Biosystems | Post-IPO Equity | 0 |
| 11/2020 | Springtide Child Development | Series A | 18M |
| 2/2023 | IronMatt | Grant | 75k |
| 6/2008 | Exelixis | Post-IPO Debt | 150M |
| 5/2012 | MAKO Surgical | Post-IPO Debt | 50M |
| 10/2020 | Olema Oncology | Series C | 85M |
| 6/2008 | ZymoGenetics | Post-IPO Debt | 100M |
| 4/2011 | Cytokinetics | Post-IPO Equity | 20M |
| 5/2017 | Synlogic | Series C | 42M |
| 3/2015 | Assertio | Post-IPO Debt | 575M |
| 3/2021 | Happify | Series D | 0 |
| 12/2011 | Flamel Technologies | Post-IPO Equity | 16M |
| 1/2018 | Concert Genetics | Venture Round | - |
| 5/2021 | Adaptive Phage Therapeutics | Series B | 40.8M |
| 12/2015 | Hallux, Inc. | Series A | 7.1M |
| 4/2022 | Aurion Biotechnologies | Venture Round | 120M |
| 5/2008 | Array BioPharma | Post-IPO Debt | 80M |
| 6/2011 | BioHorizons | Debt Financing | 50M |
| 9/2019 | Edgewise Therapeutics | Series B | 50M |
| 2/2013 | Flamel Technologies | Post-IPO Debt | 15M |
| 4/2014 | OMNILife science, Inc. | Debt Financing | 27.5M |
| 6/2020 | Meditrina, Inc | Venture Round | 10M |
| 10/2014 | SHINE Technologies | Debt Financing | - |
| 11/2018 | SHINE Medical Technologies | Debt Financing | 150M |
| 6/2020 | Somatus | Series C | 64M |
| 6/2014 | Nuo Therapeutics | Post-IPO Debt | 35M |
| 10/2014 | SHINE Technologies | Venture Round | 125M |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 1/2021 | Werewolf Therapeutics | Series B | 0 |
| 6/2010 | TALON THERAPEUTICS | Post-IPO Equity | 100M |
| 11/2017 | Fractyl Health | Series D | 0 |
| 5/2020 | Great Lakes Discoveries LLC | Funding Round | 130M |
| 7/2020 | Liquid Wire | Series A | 10M |
| 3/2014 | ATEC | Post-IPO Debt | 50M |
| 9/2013 | Intra-Cellular Therapies | Secondary Market | 60M |
| 1/2015 | REGENXBIO | Series C | 30M |
| 3/2018 | Ancora Innovation | Venture Round | 65M |
| 10/2017 | Adeptus Health | Post-IPO Debt | 257.7M |
| 11/2019 | Contessa | Series D | 32.5M |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 12/2019 | Civetta | Series A | 53M |
| 11/2007 | MiddleBrook Pharmaceuticals, Inc | Post-IPO Equity | 10M |
| 8/2014 | Epion Health | Series A | 6.8M |
| 8/2017 | MIVI Neuroscience | Debt Financing | 4M |
| 4/2008 | VIVUS | Post-IPO Debt | 20M |
| 5/2020 | ADC Therapeutics | Post-IPO Debt | 65M |
| 6/2021 | Insilico Medicine | Series C | 0 |
| 6/2016 | FogPharma | Series A | 11M |
| 1/2021 | Encodia | Series C | 75M |
| 2/2017 | Chondrial Therapeutics | Series A | 22.6M |
| 4/2022 | Acutus Medical | Post-IPO Debt | 35M |
| 6/2014 | Horizon Pharma | Post-IPO Debt | 300M |
| 7/2007 | Dynavax Technologies | Post-IPO Debt | 30M |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 12/2019 | Four Points Innovation | Funding Round | 130M |
| 10/2018 | Tris Pharma | Debt Financing | 125M |
| 2/2019 | CathWorks | Series C | 30M |
| 7/2010 | Pacific Biosciences | Series F | 0 |
| 6/2021 | Talkspace | Post-IPO Equity | 0 |
| 5/2014 | Spark Therapeutics | Series B | 72.8M |
| 10/2020 | Curation Health | Series A | - |
| 6/2021 | CareMax | Post-IPO Equity | 0 |
| 6/2018 | Lakeside Discovery | Venture Round | 65M |
| 4/2015 | Voyager Therapeutics | Series B | 0 |
| 1/2023 | Perceive Biotherapeutics | Series B | 0 |
| 4/2022 | Valneva | Post-IPO Debt | 20M |
| 4/2017 | Endologix | Post-IPO Debt | 170M |
| 12/2020 | Neomorph | Series A | 109M |
| 7/2020 | Sema4 | Series C | 121M |
| 6/2017 | Proteon Therapeutics | Post-IPO Equity | 22M |
| 5/2009 | Array BioPharma | Post-IPO Debt | 40M |
| 2/2015 | SteadyMed Therapeutics | Venture Round | 12.2M |
| 8/2015 | RedBrick Health | Venture Round | 30M |
| 6/2022 | Epic Sciences | Series F | 0 |
| 1/2020 | Vesta Healthcare | Series A | 30M |
| 7/2019 | Axon Therapies | Series A | - |
| 6/2015 | Aralez Pharmaceuticals | Post-IPO Equity | 0 |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 2/2013 | Windtree Therapeutics | Post-IPO Debt | 30M |
| 7/2020 | AdaptHealth | Post-IPO Equity | 0 |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 5/2008 | NxStage Medical | Post-IPO Equity | 5.6M |
| 5/2015 | Vital Access | Debt Financing | 10M |
| 11/2015 | Fractyl Health | Series C | 57M |
| 2/2022 | ConcertoCare | Series B | 105M |
| 1/2017 | Vescor Therapeutics | Seed Round | - |
| 3/2006 | Breathe Technologies | Series A | 4M |
| 10/2018 | Pinnacle Hill | Venture Round | 65M |
| 1/2021 | FogPharma | Series C | 107M |
| 4/2016 | Lumeris | Venture Round | 80M |
| 8/2022 | Insilico Medicine | Series D | 35M |
| 2/2021 | Spectrawave | Series A | 13.2M |
| 10/2017 | Broad Institute | Venture Round | 50M |
| 2/2021 | Xilio Therapeutics | Series C | 95M |
| 2/2018 | Collage Rehabilitation Partners | Private Equity Round | - |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 11/2016 | Recovery Centers of America | Private Equity Round | 100M |
| 1/2012 | iCAD | Post-IPO Debt | 15M |
| 5/2020 | LetsGetChecked | Series C | 71M |
| 2/2018 | Generation Bio | Series B | 100M |
| 5/2021 | Larimar Therapeutics | Post-IPO Equity | 0 |
| 2/2022 | Vibliome | Series A | 38M |
| 1/2021 | Terns Pharmaceuticals | Series C | 87M |
| 1/2016 | Advantia Health | Venture Round | - |
| 4/2023 | Cortica | Series D | 0 |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 11/2017 | Melinta Therapeutics | Post-IPO Debt | 240M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 5/2017 | Xeris Pharmaceuticals | Series C | 0 |
| 10/2016 | Bridge Medicines | Venture Round | - |
| 1/2012 | TALON THERAPEUTICS | Post-IPO Equity | 10.3M |
| 1/2015 | AveXis | Series C | 10M |
| 1/2019 | Stelexis Therapeutics | Series A | 43M |
| 11/2018 | InCarda Therapeutics | Series B | 42M |
| 6/2019 | Frontier Medicines | Series A | 67M |
| 5/2016 | GrayBug | Series B | 44.5M |
| 10/2007 | TALON THERAPEUTICS | Post-IPO Debt | 30M |
| 2/2016 | Ribon Therapeutics | Series A | 24M |
| 6/2011 | TESARO | Series B | 101M |
| 6/2021 | Adela | Series A | 60M |
| 8/2021 | Pepgen | Venture Round | 0 |
| 4/2022 | Apertura Gene Therapy | Series A | 67M |
| 5/2020 | ARTMS | Series A | 19M |
| 3/2020 | Ready | Series B | 48M |
| 1/2015 | Global Blood Therapeutics | Series B | 48M |
| 10/2014 | MedAvail | Series C | 0 |
| 1/2021 | Nuvalent | Series A | 50M |
| 7/2022 | MMI | Series B | 0 |
| 12/2007 | Third Wave Technologies | Post-IPO Equity | 25M |
| 1/2015 | Breathe Technologies | Venture Round | 810k |
| 5/2016 | Neos Therapeutics | Post-IPO Debt | 60M |
| 2/2018 | Kiniksa Pharmaceuticals | Series C | 200M |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 12/2014 | Audentes Therapeutics | Series B | 42.5M |
| 7/2010 | Nivalis Therapeutics | Series B | 0 |
| 10/2021 | DeepSight Technology | Series A | 0 |
| 9/2015 | AveXis | Series D | 65M |
| 11/2016 | Shockwave Medical | Series C | 45M |
| 11/2016 | ConcertoCare | Venture Round | 30M |
| 1/2014 | Auspex Pharmaceuticals | Series E | 0 |
| 5/2023 | Ray Therapeutics | Series A | 0 |
| 1/2020 | Generation Bio | Series C | 110M |
| 1/2016 | Syros Pharmaceuticals | Series C | 40M |
| 4/2021 | GH Research | Series B | 125M |
| 7/2016 | Oncorus | Series A | 57M |
| 2/2016 | Synlogic | Series B | 40M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 4/2018 | Arvinas | Series C | 55M |
| 3/2020 | Element Science | Series C | 145.6M |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 1/2020 | Neomorph | Seed Round | - |
| 7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
| 5/2015 | Shockwave Medical | Series B | 40M |
| 3/2018 | Pairwise Plants | Series A | 25M |
| 9/2015 | Akari Therapeutics | Post-IPO Equity | 0 |
| 6/2023 | Presidio Medical | Series C | 0 |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 5/2023 | Ray Therapeutics | Series A | 0 |
| 4/2023 | Cortica | Series D | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 2/2023 | IronMatt | Grant | 0 |
| 1/2023 | Perceive Biotherapeutics | Series B | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 11/2022 | Abeona Therapeutics | Post-IPO Equity | 0 |
| 11/2022 | Intus Care | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
